<html>
<head>
<meta http-equiv="Content-Type" content="text/html; charset=UTF-8">
<style type="text/css">
.txt { white-space:nowrap; }
#f0 { font-family:sans-serif; font-weight:normal; font-style:normal; }
#f1 { font-family:sans-serif; font-weight:normal; font-style:normal; }
#f2 { font-family:sans-serif; font-weight:bold; font-style:normal; }
@font-face { font-family: ff8; src: url("8.ttf"); }
#f3 { font-family:ff8,monospace; font-weight:normal; font-style:normal; }
@font-face { font-family: ff4; src: url("4.ttf"); }
#f4 { font-family:ff4,sans-serif; font-weight:normal; font-style:normal; }
@font-face { font-family: ff5; src: url("5.ttf"); }
#f5 { font-family:ff5,sans-serif; font-weight:normal; font-style:normal; }
@font-face { font-family: ff9; src: url("9.ttf"); }
#f6 { font-family:ff9,sans-serif; font-weight:normal; font-style:normal; }
@font-face { font-family: ff3; src: url("3.ttf"); }
#f7 { font-family:ff3,sans-serif; font-weight:normal; font-style:normal; }
@font-face { font-family: ff0; src: url("0.ttf"); }
#f8 { font-family:ff0,sans-serif; font-weight:normal; font-style:normal; }
</style>
</head>
<body>
<img id="background" style="position:absolute; left:0px; top:0px;" width="595" height="841" src="page9.png">
<div class="txt" style="position:absolute; left:56px; top:97px;"><span id="f7" style="font-size:9px;vertical-align:baseline;color:rgba(0,0,0,1);">뇌전증은 새로운 치료제의</span></div>
<div class="txt" style="position:absolute; left:56px; top:113px;"><span id="f7" style="font-size:9px;vertical-align:baseline;color:rgba(0,0,0,1);">개발이 시급</span></div>
<div class="txt" style="position:absolute; left:56px; top:305px;"><span id="f7" style="font-size:9px;vertical-align:baseline;color:rgba(0,0,0,1);">블록버스터의 가능성을</span></div>
<div class="txt" style="position:absolute; left:56px; top:321px;"><span id="f7" style="font-size:9px;vertical-align:baseline;color:rgba(0,0,0,1);">엿보다</span></div>
<div class="txt" style="position:absolute; left:56px; top:545px;"><span id="f7" style="font-size:9px;vertical-align:baseline;color:rgba(0,0,0,1);">높은 안전성</span></div>
<div class="txt" style="position:absolute; left:191px; top:95px;"><span id="f4" style="font-size:11px;vertical-align:super;color:rgba(0,0,0,1);">뇌전증이란 뇌 특정 부위에 있는 신경세포의 비정상적인 활동으로 인해 흥분</span><span id="f6" style="font-size:11px;vertical-align:super;color:rgba(0,0,0,1);">, </span><span id="f4" style="font-size:11px;vertical-align:super;color:rgba(0,0,0,1);">경</span></div>
<div class="txt" style="position:absolute; left:191px; top:111px;"><span id="f4" style="font-size:11px;vertical-align:super;color:rgba(0,0,0,1);">련</span><span id="f6" style="font-size:11px;vertical-align:super;color:rgba(0,0,0,1);">, </span><span id="f4" style="font-size:11px;vertical-align:super;color:rgba(0,0,0,1);">발작이 반복적으로 발생하여 만성화된 질환을 의미한다</span><span id="f5" style="font-size:11px;vertical-align:super;color:rgba(0,0,0,1);">. </span><span id="f4" style="font-size:11px;vertical-align:super;color:rgba(0,0,0,1);">뇌전증은 발작이 만</span></div>
<div class="txt" style="position:absolute; left:191px; top:127px;"><span id="f4" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">성화될 경우 뇌 손상은 물론이고 신체적</span><span id="f5" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">, </span><span id="f4" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">정신적 장애를 초래한다</span><span id="f5" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">. </span><span id="f4" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">뇌전증 유병률</span></div>
<div class="txt" style="position:absolute; left:191px; top:143px;"><span id="f4" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">은 전체 인구의 </span><span id="f5" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">0.5%, 200</span><span id="f4" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">명당 </span><span id="f5" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">1</span><span id="f4" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">명꼴로 </span><span id="f5" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">WHO</span><span id="f4" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">에서는 뇌전증 환자가 전 세계적</span></div>
<div class="txt" style="position:absolute; left:191px; top:159px;"><span id="f4" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">으로 약 </span><span id="f5" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">5,000</span><span id="f4" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">만명 이상 존재하는 것으로 추산한다</span><span id="f5" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">. </span><span id="f4" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">미국 </span><span id="f5" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">CDC(Centers for</span></div>
<div class="txt" style="position:absolute; left:191px; top:175px;"><span id="f5" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">Disease Control and Prevention, </span><span id="f4" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">질병통제예방센터</span><span id="f5" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">)</span><span id="f4" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">에 따르면 미국 내 뇌전증</span></div>
<div class="txt" style="position:absolute; left:191px; top:191px;"><span id="f4" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">환자 수는 </span><span id="f5" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">350</span><span id="f4" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">만명에 달하는 것으로 나타났다</span><span id="f5" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">. </span><span id="f4" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">뇌전증 전체 환자 중 </span><span id="f5" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">30~40%</span><span id="f4" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">는</span></div>
<div class="txt" style="position:absolute; left:191px; top:207px;"><span id="f5" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">1-3</span><span id="f4" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">차 치료제와 추가적인 약물까지 복용하고도 치료되지 않은 난치성 환자로 알</span></div>
<div class="txt" style="position:absolute; left:191px; top:223px;"><span id="f4" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">려져 있다</span><span id="f5" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">. </span><span id="f4" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">또한 현재 판매되고 있는 대표 약물의 난치성 환자 치료율은 </span><span id="f5" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">50%</span><span id="f4" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">에</span></div>
<div class="txt" style="position:absolute; left:191px; top:239px;"><span id="f4" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">그치는 실정으로 새로운 치료제에 대한 수요가 높은 상황이다</span><span id="f5" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">. </span><span id="f4" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">세노바메이트는</span></div>
<div class="txt" style="position:absolute; left:191px; top:255px;"><span id="f4" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">기존 뇌전증 치료제에 반응하지 않는 난치성 환자를 대상으로 개발되었기 때문에</span></div>
<div class="txt" style="position:absolute; left:191px; top:271px;"><span id="f4" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">시장의 </span><span id="f5" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">unmet needs(</span><span id="f4" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">미충족 수요</span><span id="f5" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">)</span><span id="f4" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">를 만족시킬 수 있을 전망이다</span><span id="f5" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">.</span></div>
<div class="txt" style="position:absolute; left:191px; top:303px;"><span id="f4" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">세노바메이트는 뇌에서 흥분 신호를 전달하는 나트륨</span><span id="f5" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">(Na+) </span><span id="f4" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">채널의 나트륨 이온</span></div>
<div class="txt" style="position:absolute; left:191px; top:319px;"><span id="f4" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">전류</span><span id="f5" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">(persistent sodium current, INap)</span><span id="f4" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">를 차단함과 동시에 억제성 신호전달에</span></div>
<div class="txt" style="position:absolute; left:191px; top:335px;"><span id="f4" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">관여하는 </span><span id="f5" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">GABA-A </span><span id="f4" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">수용체의 알로스테릭을 활성화하여 신경세포의 신경전달 과</span></div>
<div class="txt" style="position:absolute; left:191px; top:351px;"><span id="f4" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">정을 정상으로 조절하는 것으로 파악된다</span><span id="f5" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">. </span><span id="f4" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">뇌전증의 원인이 되는 흥분성</span><span id="f5" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">/</span><span id="f4" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">억제성</span></div>
<div class="txt" style="position:absolute; left:191px; top:367px;"><span id="f4" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">신호전달과 관련된 두 가지 타깃을 동시에 조절해 신경세포의 흥분</span><span id="f5" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">/</span><span id="f4" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">억제 균형을</span></div>
<div class="txt" style="position:absolute; left:191px; top:383px;"><span id="f4" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">정상화하는 방식이다</span><span id="f5" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">. </span><span id="f4" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">세노바메이트는 </span><span id="f5" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">2008</span><span id="f4" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">년부터 건강인을 대상으로 임상 </span><span id="f5" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">1</span><span id="f4" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">상</span></div>
<div class="txt" style="position:absolute; left:191px; top:399px;"><span id="f4" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">을 완료한 후 </span><span id="f5" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">2015</span><span id="f4" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">년 뇌전증 환자 대상으로 임상 </span><span id="f5" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">2</span><span id="f4" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">상을 마치고 </span><span id="f5" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">2018</span><span id="f4" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">년 임상 </span><span id="f5" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">3</span></div>
<div class="txt" style="position:absolute; left:191px; top:415px;"><span id="f4" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">상을 완료했다</span><span id="f5" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">. </span><span id="f4" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">임상 </span><span id="f5" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">3</span><span id="f4" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">상은 전 세계 </span><span id="f5" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">17</span><span id="f4" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">개국</span><span id="f5" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">, 125</span><span id="f4" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">개 사이트에서 환자 </span><span id="f5" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">1,348</span><span id="f4" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">명을</span></div>
<div class="txt" style="position:absolute; left:191px; top:431px;"><span id="f4" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">대상으로 진행했다</span><span id="f5" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">. </span><span id="f4" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">지난 </span><span id="f5" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">2016</span><span id="f4" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">년 </span><span id="f5" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">FDA</span><span id="f4" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">가 세노바메이트의 임상 </span><span id="f5" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">2</span><span id="f4" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">상 효능을 인정</span></div>
<div class="txt" style="position:absolute; left:191px; top:447px;"><span id="f4" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">함에 따라 임상 </span><span id="f5" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">3</span><span id="f4" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">상에서는 안전성과 약물동력학만 평가만으로 </span><span id="f5" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">NDA </span><span id="f4" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">신청이 가능</span></div>
<div class="txt" style="position:absolute; left:191px; top:463px;"><span id="f4" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">했다</span><span id="f5" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">. </span><span id="f4" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">뇌전증 치료제는 전세계적으로 </span><span id="f5" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">UCB</span><span id="f4" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">제약의 빔팻</span><span id="f5" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">(Vimpat, </span><span id="f4" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">성분명</span><span id="f5" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">:</span></div>
<div class="txt" style="position:absolute; left:191px; top:479px;"><span id="f5" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">lacosamide)</span><span id="f4" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">이 시장을 선도하고 있다</span><span id="f5" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">. </span><span id="f4" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">임상 </span><span id="f5" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">2</span><span id="f4" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">상에서 세노바메이트는 플라시보와</span></div>
<div class="txt" style="position:absolute; left:191px; top:495px;"><span id="f4" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">빔팻 대비 발작 빈도수 감소율이 높아 뛰어난 효능을 나타내면서 블록버스터의</span></div>
<div class="txt" style="position:absolute; left:191px; top:511px;"><span id="f4" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">가능성을 보여줬다</span><span id="f5" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">.</span></div>
<div class="txt" style="position:absolute; left:191px; top:543px;"><span id="f4" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">한편 세노바메이트는 안전성도 뛰어난 것으로 밝혀졌다</span><span id="f5" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">. </span><span id="f4" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">임상 </span><span id="f5" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">3</span><span id="f4" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">상에서 가장 집중</span></div>
<div class="txt" style="position:absolute; left:191px; top:559px;"><span id="f4" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">된 부분은 안전성으로 대부분의 뇌전증 약물 복용시에 발생하는 </span><span id="f5" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">DRESS </span><span id="f4" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">증후군</span></div>
<div class="txt" style="position:absolute; left:191px; top:575px;"><span id="f5" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">(Drug rash with eosinophilia and systemic symptoms syndrome)</span><span id="f4" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">의 발생 여</span></div>
<div class="txt" style="position:absolute; left:191px; top:591px;"><span id="f4" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">부였다</span><span id="f5" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">. DRESS </span><span id="f4" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">증후군은 뇌전증 치료제의 흔한 부작용으로 일종의 약물 알레르</span></div>
<div class="txt" style="position:absolute; left:191px; top:607px;"><span id="f4" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">기로 심각한 발진뿐 아니라 급성간염</span><span id="f5" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">, </span><span id="f4" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">신부전을 일으켜 사망에 이를 수 있는 심각</span></div>
<div class="txt" style="position:absolute; left:191px; top:623px;"><span id="f4" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">한 질환이다</span><span id="f5" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">. </span><span id="f4" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">임상 </span><span id="f5" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">3</span><span id="f4" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">상에서는 총 </span><span id="f5" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">1,348</span><span id="f4" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">명의 환자를 모집했는데 그중 </span><span id="f5" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">1,037</span><span id="f4" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">명이</span></div>
<div class="txt" style="position:absolute; left:191px; top:639px;"><span id="f5" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">28</span><span id="f4" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">주간 세노바메이트를 복용했으며 </span><span id="f5" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">273</span><span id="f4" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">명은 임상 도중 치료를 중단했다</span><span id="f5" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">. 114</span><span id="f4" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">명</span></div>
<div class="txt" style="position:absolute; left:191px; top:655px;"><span id="f5" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">(8.5%)</span><span id="f4" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">에서 입원치료가 필요한 경련을 포함하는 부작용이 관찰됐으며 가장 흔한</span></div>
<div class="txt" style="position:absolute; left:191px; top:671px;"><span id="f4" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">부작용은 졸음</span><span id="f5" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">, </span><span id="f4" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">어지럼증</span><span id="f5" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">, </span><span id="f4" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">피로였다</span><span id="f5" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">. DRESS </span><span id="f4" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">증후군은 한 건도 관찰되지 않았다</span><span id="f5" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">.</span></div>
<div class="txt" style="position:absolute; left:191px; top:687px;"><span id="f4" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">임상 </span><span id="f5" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">2</span><span id="f4" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">상에서는 세 건이 발견되었으나 감소된 첫 시작 용량과 </span><span id="f5" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">2</span><span id="f4" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">주라는 용량 적정</span></div>
<div class="txt" style="position:absolute; left:191px; top:703px;"><span id="f4" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">기간이 </span><span id="f5" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">DRESS </span><span id="f4" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">증후군 발병을 줄일 수 있었다</span><span id="f5" style="font-size:11px;vertical-align:baseline;color:rgba(0,0,0,1);">.</span></div>
<div class="txt" style="position:absolute; left:64px; top:802px;"><span id="f1" style="font-size:9px;vertical-align:baseline;color:rgba(128,128,128,1);">8</span></div>
</body>
</html>
